Teva’s Anti-IL-15 Antibody Meets Main Goal in Celiac Disease Study
Teva’s TEV ’408 met its Phase 2a primary endpoint in celiac disease, limiting gluten-induced intestinal damage after one subcutaneous dose.
/ 491 items
#XY Event-Driven Stocks↓
Enovis Stock Slides After €155 Million eCential Robotics Offer
Near-term dilution and leverage outweighed the longer robotics strategy.
Invivyd Promotes Marc Elia to CEO and Maps Dual Path for VYD2311 Data
Cantor keeps Overweight and a $10 target after the stock drop.
Mixed Phase 2b Results for Alumis Lupus Drug; Company Eyes Phase 3 in Subgroup
Alumis’ Phase 2b LUMUS trial of envudeucitinib missed overall SLE endpoints but showed robust responses in IFNGS-high patients. Psoriasis NDA still set for Q4 2026.
Novartis Pauses Cell Therapy Trials After Three Deaths as MS Pill Succeeds in Late-Stage Studies
Three deaths halt Novartis rap-cel trials in autoimmune disease. Positive Phase 3 data for remibrutinib in relapsing MS announced the same day.
Hims & Hers Launches in Australia With Online Men’s Health and Weight-Loss Care
Hims launches nationwide men’s care in Australia after buying Eucalyptus.